Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31626948 | 0.84 | — | — | |
| SCHEMBL284829 | 0.75 | PDPK1 (0.52) | PDPK1 | |
| SCHEMBL30984104 | 0.74 | ADORA2A (0.34) | — | |
| SCHEMBL2940695 | 0.73 | PDPK1 (0.36) | PDPK1LRRK2 | |
| Bromide SCHEMBL31626878 | 0.73 | ADORA2A (0.33) | — | |
| SCHEMBL3388862 | 0.73 | KDM4E (0.40) | PDPK1LRRK2 | |
| SCHEMBL31269071 | 0.69 | LIMK1 (0.33) | — | |
| SCHEMBL22639807 | 0.69 | CDK1 (0.48) | PDPK1 | |
| SCHEMBL17924977 | 0.69 | PDPK1 (0.34) | PDPK1 | |
| SCHEMBL13369897 | 0.68 | PDPK1 (0.33) | PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| US-12414954-B2 | POLQ inhibitors | ASTRAZENECA AB (SE) | 2025-09-16 | — | — | US | disclosed |
| US-20250195530-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| US-20240366615-A1 | POLQ INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 2024-11-07 | — | — | US | disclosed |
| WO-2024121753-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366615-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | PDPK1 1079/4885LRRK2 3622/4885 |
| US-12414954-B2 | POLQ inhibitors | POLQ, POLG, POLB | PDPK1 1079/4885LRRK2 3622/4885 |
| US-20250195530-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | PDPK1 1079/4885LRRK2 3622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.